RENE GONZALEZ to MAP Kinase Kinase 1
This is a "connection" page, showing publications RENE GONZALEZ has written about MAP Kinase Kinase 1.
Connection Strength
0.551
-
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020 04; 85(4):673-683.
Score: 0.165
-
Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
Score: 0.161
-
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 01; 31(4):482-9.
Score: 0.101
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug; 13(8):782-9.
Score: 0.098
-
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol. 2013 May 10; 31(14):1767-74.
Score: 0.026